186 related articles for article (PubMed ID: 31041788)
1. Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.
Nault JC; Letouzé E
Semin Liver Dis; 2019 Jul; 39(3):334-340. PubMed ID: 31041788
[TBL] [Abstract][Full Text] [Related]
2. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
4. The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
Lu ZN; Luo Q; Zhao LN; Shi Y; Wang N; Wang L; Han ZG
Hepatology; 2020 Mar; 71(3):929-942. PubMed ID: 31692012
[TBL] [Abstract][Full Text] [Related]
5. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
6. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer.
Arlt VM; Alunni-Perret V; Quatrehomme G; Ohayon P; Albano L; Gaïd H; Michiels JF; Meyrier A; Cassuto E; Wiessler M; Schmeiser HH; Cosyns JP
Int J Cancer; 2004 Oct; 111(6):977-80. PubMed ID: 15300815
[No Abstract] [Full Text] [Related]
8. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
9. Recognition of the toxicity of aristolochic acid.
Zhang HM; Zhao XH; Sun ZH; Li GC; Liu GC; Sun LR; Hou JQ; Zhou W
J Clin Pharm Ther; 2019 Apr; 44(2):157-162. PubMed ID: 30548302
[TBL] [Abstract][Full Text] [Related]
10. [Aristolochic acid nephropathy ("Chinese herb nephropathy")].
Nortier J; Pozdzik A; Roumeguere T; Vanherweghem JL
Nephrol Ther; 2015 Dec; 11(7):574-88. PubMed ID: 26515658
[TBL] [Abstract][Full Text] [Related]
11. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
12. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
13. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
14. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
[TBL] [Abstract][Full Text] [Related]
15. Carcinogens that induce the A:T > T:A nucleotide substitutions in the genome.
Zhou G; Zhao X
Front Med; 2018 Apr; 12(2):236-238. PubMed ID: 29209916
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between aristolochic acid exposure and hepatocellular carcinoma.
Ji X; Feng G; Chen G; Shi T
Sci China Life Sci; 2018 Jun; 61(6):727-728. PubMed ID: 29700703
[No Abstract] [Full Text] [Related]
17. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acid and the etiology of endemic (Balkan) nephropathy.
Grollman AP; Shibutani S; Moriya M; Miller F; Wu L; Moll U; Suzuki N; Fernandes A; Rosenquist T; Medverec Z; Jakovina K; Brdar B; Slade N; Turesky RJ; Goodenough AK; Rieger R; Vukelić M; Jelaković B
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12129-34. PubMed ID: 17620607
[TBL] [Abstract][Full Text] [Related]
19. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
Chen CJ; Yang YH; Lin MH; Lee CP; Tsan YT; Lai MN; Yang HY; Ho WC; Chen PC;
Int J Cancer; 2018 Oct; 143(7):1578-1587. PubMed ID: 29667191
[TBL] [Abstract][Full Text] [Related]
20. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure.
Nortier JL; Schmeiser HH; Muniz Martinez MC; Arlt VM; Vervaet C; Garbar CH; Daelemans P; Vanherweghem JL
Nephrol Dial Transplant; 2003 Feb; 18(2):426-8. PubMed ID: 12543902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
